터너스팜즈(TERN) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

🏛️

거래 정지 중인 종목 2026-06-04 이후 거래가 정지되었습니다. 재개될 수 있으며, 표시된 시세는 마지막 거래일 기준입니다.

TERN

Terns Pharmaceuticals Inc

$52.95

+0.00 +0.00%

터너스팜즈(TERN) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$6.1B

스몰캡

P/E

배당수익률

없음

52주 위치

100%

저점 +1894% · 고점 -0%

애널리스트

보유

Fundamental health

vs. 방어주 중형주· based on 2 axes

수익성

산출 불가 (적자)

성장

Top 74%

밸류에이션

데이터 부족

재무 안정

Top 33%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-1.03	Insider Own ⓘ	8.72%	Shs Outstand ⓘ	112.3M	Perf Week ⓘ	-
Market Cap ⓘ	6.12B	Forward P/E ⓘ	-	EPS next Y ⓘ	-29.01%	Insider Trans ⓘ	-1.67%	Shs Float ⓘ	105.5M	Perf Month ⓘ	0.46%
Enterprise Value ⓘ	5.10B	PEG ⓘ	-	EPS next Q ⓘ	-0.28	Inst Own ⓘ	103.06%	Short Float ⓘ	5.25%	Perf Quarter ⓘ	40.26%
Income ⓘ	-0.10B	P/S ⓘ	-	EPS this Y ⓘ	-20.18%	Inst Trans ⓘ	-	Short Ratio ⓘ	0.96	Perf Half Y ⓘ	157.29%
Sales ⓘ	0.00B	P/B ⓘ	5.91	EPS next 5Y ⓘ	-22.36%	ROA ⓘ	-13.85%	Short Interest ⓘ	5.54M	Perf YTD ⓘ	31.06%
Book/sh ⓘ	8.96	P/C ⓘ	6	EPS past 3/5Y ⓘ	14.89% 2.44%	ROE ⓘ	-14.23%	52W High ⓘ	-0.45% ($53.19)	Perf Year ⓘ	1412.86%
Cash/sh ⓘ	8.82	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-	ROIC ⓘ	-9.55%	52W Low ⓘ	1894.35% ($2.65)	Perf 3Y ⓘ	321.24%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	8.38%	Gross Margin ⓘ	-	Volatility(W/M) ⓘ	0.07% 0.18%	Perf 5Y ⓘ	185.91%
Dividend TTM ⓘ	-	EV/Sales ⓘ	-	Sales Y/Y TTM ⓘ	-	Oper. Margin ⓘ	-	ATR (14) ⓘ	0.43	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	62.41	EPS Q/Q ⓘ	-0.25%	Profit Margin ⓘ	-	RSI (14) ⓘ	73.93	Recom ⓘ	3
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	62.41	Sales Q/Q ⓘ	-	SMA20 ⓘ	0.32% ($52.78)	Beta ⓘ	-0.41	Target Price ⓘ	$53
Payout ⓘ	-	Debt/Eq ⓘ	0	Earnings ⓘ	2026/03/31	SMA50 ⓘ	7.6% ($49.21)	Rel Volume ⓘ	0	Prev Close ⓘ	$52.95
Employees ⓘ	59	LT Debt/Eq ⓘ	0	EPS/Sales Surpr. ⓘ	-4.24% -	SMA200 ⓘ	90.8% ($27.75)	Avg Volume(3M) ⓘ	5.79M	Price ⓘ	$52.95
IPO ⓘ	2021/2/5	Option/Short ⓘ	Yes/No			Trades ⓘ	0	Volume ⓘ	-	Change ⓘ	-

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Terns Pharmaceuticals Inc (TERN) Investment Analysis

What kind of company is Terns Pharmaceuticals Inc?

터너스팜즈(TERN) 방어주

Healthcare · Biotechnology

#1205 by Market Cap — Mid-Cap

💊 Terns Pharmaceuticals (TERN) is a U.S.-headquartered, clinical-stage biotech company that has been focused on developing oral small-molecule therapies. Its lead asset is TERN-701, an oral allosteric tyrosine kinase inhibitor (TKI) targeting chronic myeloid leukemia (CML), and historically it has also developed a portfolio of oral obesity treatment candidates in the obesity and metabolic disease space. It is a typical drug-development biotech whose enterprise value is driven by clinical progress in its oncology pipeline.

Learn more about Terns Pharmaceuticals Inc →

Market Cap

$6.1B

Approx. KRW 8.4 trillion

⚖️ 2% of Samsung Electronics

Market Cap Rank1205

Employees59people

IPO2021/02/05

Current Price$52.95 ≈ 72,542원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 3월 31일 (화) · 장 마감 후 EPS -4.2%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-14.2%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-13.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-9.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.00

✓ Very low debt

My positionTop 5%

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

62.41

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology Median 5.74

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

62.41

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$53.00

현재가 대비 +0.1%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

-29.0%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

-22.4%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-4.2%

평균 서프라이즈

2026.03.31

하회

-4.2%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Concerns

Growth is lagging the industry average

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-20.2%

부진

My positionBottom 25%

Low range Average High range

방어주 중형주 Median 5.2% · Bottom 22%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

-29.0%

매우 부진

My positionBottom 5%

Low range Average High range

방어주 중형주 Median 10.6% · Bottom tier

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

-22.4%

매우 부진

My positionBottom 5%

Low range Average High range

방어주 중형주 Median 7.3% · Bottom tier

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+14.9%

양호

My positionMid-range

Low range Average High range

방어주 중형주 Median 4.9% · Top 32%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+2.4%

평균

My positionMid-range

Low range Average High range

방어주 중형주 Median 6.5% · Bottom 43%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Outperformed the market by 117%p over 5 years

TERN +185.9% · S&P 500 +68.8%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

+117.1%p

well ahead of the market

vs Health Care (XLV)

+158.9%p

well ahead of the sector average

1-year basis

vs S&P 500

+1396.5%p

well ahead of the market

vs Health Care (XLV)

+1389.2%p

well ahead of the sector average

Rank among peers

5-year return Upper-Mid (26%) Based on 64 peers

1-year return Top among peers Based on 74 peers

Current position within 52-week range

Low (-1894.3%p) High (-0.5%p)

Current price is 1894.3% above the 52-week low and 0.5% below the 52-week high

Recent risk (last 81 trading days)

Max drawdown

-8.3%

Annualized volatility

33.3%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 88-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟡

Current diagnosis · 2026-05-15

Squeeze — volatility contraction, breakout imminent

Band width narrowed to 0.4%. Big move may be near. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-05-15

Neutral zone — weak trend

MACD 0.516 · Signal 0.716 · Hist -0.200. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

⚠️

Current diagnosis · 2026-05-15

Overbought zone — short-term pullback possible

RSI 73.9 (above 70). Buying pressure is excessive, and profit-taking may emerge. Stoch %K is also 50.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Assets

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Cheap

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

5.91x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 중형주 median 6.69x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

Analyst target price (reference)

$53.00 vs. current price +0.1%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 중형주

Who owns it?

Ownership is broadly stable

Insider modest net selling -1.7% · Short interest moderate 5.3% · Short interest fell -11.5%p over the last 81 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-1.7%

Insiders net selling

🏦 Institutions (funds & investors)

No trading data for Institutions

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 103.1%

Institution-led, stable structure

Healthcare 중형주 Median 89.7%

🧑‍💼 Insiders 8.7%

Meaningful insider stake

Healthcare 중형주 Median 9.4%

👤 Retail investors (estimated) 0.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

5.3%

Moderate

Healthcare 중형주 Median 10.8%

Past 81 days 📉 -11.5%p decrease

Short interest days to cover

1.0 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 112.3M주

Float (tradable shares) 105.5M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 81 days.

ETFs holding TERN

ETFs with the highest weightings · 10 total shown

PTH

Invesco Dorsey Wright Healthcare Momentum ETF

2.86%

$231M

XPH

State Street SPDR S&P Pharmaceuticals ETF

2.16%

$479M

MNA

NYLI Merger Arbitrage ETF

1.74%

$252M

DWAS

Invesco Dorsey Wright SmallCap Momentum ETF

1.58%

$434M

PILL

Direxion Daily Pharmaceutical & Medical Bull 3X ETF

1.51%

$21M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
TERN This Stock	$6.1B	-	5.9 ▼	-14.23% ▲	-	+0.0%
LLY	$1.15T	43.9 ▼	36.9 ▼	107.64% ▲	0.57% ▼	+1.9%
JNJ	$642.8B	30.9 ▼	7.6 ▼	25.74% ▲	2.02% ▲	+0.3%
ABBV	$465.0B	129.8 ▼	-	15221.82% ▲	2.61% ▲	+2.5%
UNH	$389.4B	27.6 ▼	4.0 ▼	12.49% ▲	2.11% ▲	+2.7%
MRK	$325.6B	37.1 ▼	7.1 ▼	18.97% ▲	2.48% ▲	+0.8%
Sector Avg	-	26.4	2.6	-48.94%	1.16%	-

Derivative ETFs for TERN

Leveraged, inverse, and covered call ETFs based on the underlying asset

17 derivative ETFs based on TERN (Leverage 7 · Inverse 2 · Covered Call 8)

These are based on the same underlying asset but carry a completely different risk and return profile. Please review the warning below first.

ℹ️ What is a Derivative ETF?

These are special ETFs that amplify, reverse, or monetize the price movement of an underlying ETF or security. Leveraged ETFs aim for 2–3× the daily move, Inverse ETFs target opposite-direction returns, and Covered Call ETFs generate monthly income from option premiums.

⚠️ Caution: Long-Term Holding

Leveraged and inverse ETFs track only the daily return. With high volatility, holding them for longer periods causes cumulative volatility decay—returns diverge further from the underlying index. They are meant for short-term trading.

📈 Leverage 7 ETFs that move 2-3x with TERN (high volatility)